VMS Vortex Metals Inc

NOT FOR DISSEMINATION IN THE UNITED STATES

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX
VENTURE:VPT) is pleased to announce the closing of a previously announced
private placement of Units (the "Units") of the Corporation (the "Offering").
Pursuant to the Offering, the Corporation issued 183,209 Units at a price of
$1.00 per Unit for gross proceeds of $183,209. Each Unit consists of a Secured
Debenture Promissory Note the ("Debenture") with an interest rate of 8% per
annum and four share purchase warrants (the "Warrants") of the Corporation. Each
Warrant is exercisable into one common share of the Corporation (the "Common
Share") at an exercise price of $0.15 per Common Share for a period of three
years from the date of issuance. The Debentures have a maturity date of three
years from the date of issuance and are redeemable at the option of the
Corporation any time after one year from the date of issuance.


In conjunction with the Offering, VentriPoint paid a cash commission of
$12,410.55 and issued 49,642 non-transferable warrants exercisable into Common
Shares at a price of $0.15 per Common Share for a period of three (3) years from
the date of issue. All securities issued pursuant to the Offering are subject to
a four-month hold period pursuant to applicable securities legislation. The
proceeds made available through the sale of Units will be used to incur
expenditures in preparation for and implementation of product and service
commercialization and for working capital purposes.


The Corporation also announces that, subject to the approval of the TSX Venture
Exchange ("TSXV"), it has entered into a non-arm's length agreement whereby the
Corporation will issue 1,142,460 Units in satisfaction of certain outstanding
debt obligations. The Units will be issued on the same terms as the Offering and
are subject to a four-month hold period pursuant to applicable securities
legislation.


Pursuant to the Corporation's press release dated April 17, 2009, the
Corporation also announces that it did not proceed with its previously announced
issuance of shares of the Corporation in satisfaction of outstanding debt
obligations. The Corporation intends to, subject to the approval of the TSXV, to
issue, 424,159 common shares in the capital of the Corporation to non-officer
directors, consultants as payment for services rendered from July 2008 through
December 2008. The issuances of common shares to non-officers directors is in
accordance with agreements which provide that such directors shall each receive
a total of 90,000 common shares as compensation for serving as a director and
committee member for their first year of service. In addition, the Corporation
intends to issue 581,211 common shares to employees and former employees in
recognition of the delivery of critical development milestones ahead of
schedule, in accordance with the 2007 incentive plan of the Corporation for the
year ended 2008, as well as 645,268 common shares for outstanding salaries for
the months of April 2008 through May 2008 and 12,251 common shares as part of
the Corporation's employee retention plan. All common shares will be issued at a
price of $0.075 per share and are subject to a four-month hold period pursuant
to applicable securities legislation.


About VentriPoint Diagnostics Ltd.

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. Health Canada has granted licensed approval for the VMS
breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
developed for a variety of heart related disease states, including congenital
heart disease and pulmonary hypertension.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the Subject line.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024